Genomic Alterations as Inclusion Criteria in Oncology Trials
Genomic inclusion criteria align the investigational therapy’s mechanism of action with patients most likely to benefit. Instead of enrolling “all‑comers,” you prospectively select participants with actionable alterations—EGFR exon 19 deletions, ALK/RET fusions, BRAF V600E, BRAFV600K, BRCA1/2 pathogenic variants, IDH1 R132H, NTRK fusions, and so on—so that the observed treatment effect reflects target engagement rather than chance. This approach increases biological signal, reduces sample size, and can support expedited pathways when effect sizes are large. That said, “genomics‑only” eligibility is not automatically optimal. In tumors with low alteration prevalence or uncertain predictive value, overly narrow criteria can cripple accrual, inflate screen‑fail rates, and introduce spectrum bias (you only study patients with extensive prior testing and access). A principled decision requires: (1) strong translational evidence that the alteration is predictive, not merely prognostic; (2) an analytical pipeline capable of reliably detecting the alteration; and (3) a trial design that preserves internal validity while remaining feasible across regions and labs.
Click to read the full article.